Blood transfusion in burn patients: Triggers of transfusion in a referral burn center in Iran

Evaluation of blood product transfusion therapies in acute injury care in low- and middle-income countries: a systematic review

“…With the far-reaching impacts of injuries in LMICs [ 1-5 , 29 ] and the limited available research from these settings, additional study of blood product therapies, which are key to combating injury-related mortality, is crucial for informing clinical practice and policy. [42] 3, 5 Low Javali (2017) [43] 3 Moderate Kilyewala (2017) [57] 3, 4, 5 Very Low London (2001) [41] 2, 4 Low Mofidi (2010) [47] 2, 4, 5 Very Low Musau (2006) [50] 3, 4 Low Newton (2015) [51] 1, 3, 4, 5 Very Low Otieno (2004) [52] 3, 4 Low Sadeghi (2017) [48] 2, 3 Low Saidi (2014) [53] 3, 5 Low Sokhal (2017) [44] 3, 5 Low Srikant (2003) [45] 1, 3, 4 Very Low Tavousi (2018) [49] 3, 5 Low Yanar (2008) [56] 3 There is substantial research, including well-performed RCTs from HICs, that has led to development of consensus guidelines on the use of blood products in the treatment of acute injuries [ 14-16 , 18 , 59 , 60 ] [ 8 , 18 , 61 , 62 ]. Even though the global burden of injuries lies predominantly in LMICs [ 1-5 , 29 ], this systematic review demonstrates that there is a paucity of high-quality research from these settings.…”

“…Included reports were derived from Ghana (1) [41] , India (4) [42][43][44][45] , Iran (4) [46][47][48][49] , Kenya (4) [50][51][52][53] , South Africa (2) [ 54 , 55 ], Turkey (1) [56] and Uganda (1) [57] . The cumulative number of patients studied in all reports was 6535.…”

“…2 . The majority of patients studied were from the African Region (52.5%) [ 41 , 50-53 , 57 ], with smaller percentages from the South-East Asia Region [42][43][44][45] , European Region [56] and Eastern Mediterranean Region [46][47][48][49] . There was limited representation of nations within each WHO region, as only one country was represented in the European Region, one in the Eastern Mediterranean Region, one in the South-East Asia Region, and four in the African Region.…”

“…The majority of reports did not specify types of blood products used (64.7%) [ 42-47 , 50-53 , 57 ]. Three reports provided data solely on PRBCs (17.6%) [ 48 , 55 , 56 ], one of which examined allogenic and autologous PRBCs [54] , and one report provided data on the use of PRBCs, FFP, platelets, and cryoprecipitate [49] . Evalua-tion of patient level data extracted from the reports demonstrated that of the 881 patients who received blood products, 50.1% received unspecified blood products, 27.0% received PRBCs, 13.8% received FFP, 8.3% received whole blood, 0.7% received platelets and 0.1% received cryoprecipitate ( Fig.…”

Viral Infections in Burn Patients: A State-Of-The-Art Review

“…Other factors, such as a burn greater than 20% of the TBSA, a low BMI status, and abnormal white blood cell counts, might be potential indicators during consideration for blood transfusion [139]. Tavousi et al showed that, in a group of 701 burn patients, the mortality rate was two times higher among patients who had received blood transfusions compared to groups that were not treated with any blood products [140]. To date, there is no strategy to prevent HIV transmissions during blood perfusions [137].…”